炎症性肠病生物治疗的不良反应及安全性研究进展  

Study advances in adverse reactions and safety of biotherapy for inflammatory bowel disease

作　　者：高阳[1] 胡美莲 邵佩 王丽波[1] GAO Yang;HU Meilian;SHAO Pei;WANG Libo(Department of Gastroenterology,First Hospital of Jilin University,Changchun,Jilin 130021,China)

机构地区：[1]吉林大学第一医院胃肠内科

出　　处：《重庆医学》2020年第3期504-509,共6页Chongqing medicine

摘　　要：炎症性肠病(IBD)是一类多种病因引起的肠道慢性炎症,近年来我国IBD患病人数呈上升趋势,生物制剂应用也逐渐增多。生物制剂对大部分IBD患者(包括儿童)能起到长期维持缓解、促进组织愈合、降低住院率与手术率的作用,但自从其应用于临床以来,陆续发现了许多不良反应及安全隐患。本文结合国内外文献及报道,主要对生物制剂的不良反应及安全问题研究进展进行综述。Inflammatory bowel disease(IBD)is a chronic intestinal inflammation caused by multiple etiologies.In recent years,the number of the patients with IBD in our country shows a increasing trend,and the application of biological agents has gradually increased.Biologics can play the roles for long-term maintaining relief,promoting the tissue healing,reducing the hospitalization rate and surgical rate in most IBD patients(including children),but since its application in clinic,many adverse reactions and hidden safety hazards have been discovered.This paper mainly reviews the research progress on adverse reactions and safety of biological agents by combining with domestic and foreign literatures and reports.

关 键 词：炎症性肠病 生物因子 抗肿瘤坏死因子 药物相关性副作用和不良反应 安全问题 

分 类 号：R574.6[医药卫生—消化系统]